Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.880
0.00 (0.00%)
Apr 29, 2026, 10:58 AM EDT - Market open

Inhibikase Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-48.26-27.52-19.03-18.05-14.79
Upgrade
Depreciation & Amortization
0.060.030.180.01-
Upgrade
Asset Writedown & Restructuring Costs
7.36----
Upgrade
Stock-Based Compensation
15.318.140.50.461.53
Upgrade
Other Operating Activities
-2.31-0.030.070.72
Upgrade
Change in Accounts Receivable
--0.040.07-0.11
Upgrade
Change in Accounts Payable
0.150.27-0.50.06-0.63
Upgrade
Change in Unearned Revenue
-----2.33
Upgrade
Change in Other Net Operating Assets
-0.09-0.070.70.041.3
Upgrade
Operating Cash Flow
-27.79-19.15-18.09-17.35-14.3
Upgrade
Capital Expenditures
-0.01--0.01-0.24-
Upgrade
Sale (Purchase) of Intangibles
-0.44----
Upgrade
Investment in Securities
2.51-3711.67-15.76-
Upgrade
Investing Cash Flow
2.05-3711.66-16.01-
Upgrade
Long-Term Debt Repaid
----0.25-0.04
Upgrade
Total Debt Repaid
----0.25-0.04
Upgrade
Net Debt Issued (Repaid)
----0.25-0.04
Upgrade
Issuance of Common Stock
108.46103.488.540.0441.21
Upgrade
Repurchase of Common Stock
-----0.08
Upgrade
Other Financing Activities
---0.14--
Upgrade
Financing Cash Flow
108.46103.488.41-0.241.09
Upgrade
Net Cash Flow
82.7347.331.98-33.5626.8
Upgrade
Free Cash Flow
-27.8-19.15-18.1-17.59-14.3
Upgrade
Free Cash Flow Margin
---6947.87%-14253.37%-461.10%
Upgrade
Free Cash Flow Per Share
-0.28-0.81-3.00-4.17-4.71
Upgrade
Cash Interest Paid
---00
Upgrade
Levered Free Cash Flow
-9.56-8.93-12.17-10.97-9.47
Upgrade
Unlevered Free Cash Flow
-9.56-8.93-12.17-10.97-9.46
Upgrade
Change in Working Capital
0.060.20.230.17-1.76
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.